Core Viewpoint - The company, LIZHU PHARMACEUTICAL (01513.HK), has announced a strategic transaction involving capital increase and equity transfer agreements with Health元 and two other entities, focusing on optimizing its asset structure and enhancing governance efficiency [1] Group 1: Transaction Details - The agreement stipulates that "心有毛孩" will increase its capital contribution to "毛孩子" by RMB 15 million, while Health元 will transfer its 49% equity stake in "毛孩子" to "心有毛孩" [1] - Following the completion of this transaction, "心有毛孩" will hold 52.56% of "毛孩子," while the company's stake will be diluted from 51.00% to 47.44%, and Health元 will no longer hold any equity in "毛孩子" [1] Group 2: Strategic Focus - The company is strategically focusing on pharmaceutical research, production, and sales, while recognizing the growth potential in the pet medicine industry represented by "毛孩子" [1] - This transaction is seen as a significant step for the company to concentrate resources on its core business, allowing for sustained sharing of "毛孩子's" long-term growth potential [1] Group 3: Future Implications - Post-transaction, the company plans to allocate more energy and resources towards technological innovation and market expansion within the pharmaceutical sector, aiming to further solidify and enhance its profitability [1] - This move aligns with the company's long-term development strategy and the overall interests of all shareholders [1]